Eleven auto-antibodies that could distinguish serous ovarian cancer from benign disease (with 32% sensitivity) and healthy controls (45% sensitivity) at 98% specificity were found, five of which have been previously identified in serous ovarian cancer (p53 and CTAG2) or related cancers (NUDT11, PVR, and TRIM39) as contributing to cancer progression. This evidence concerns the gene PVR and ovarian serous adenocarcinoma.